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Abstract: Heme oxygenase 1 (HO-1) and carbon monoxide were shown to normalize oxidative stress
and inflammatory reactions induced by neuropathic pain in the central nervous system, but their
effects in the locus coeruleus (LC) of animals with peripheral inflammation and their interaction
with nitric oxide are unknown. In wild-type (WT) and knockout mice for neuronal (NOS1-KO) or
inducible (NOS2-KO) nitric oxide synthases with inflammatory pain induced by complete Freund’s
adjuvant (CFA), we assessed: (1) antinociceptive actions of cobalt protoporphyrin IX (CoPP), an
HO-1 inducer; (2) effects of CoPP and tricarbonyldichlororuthenium(II) dimer (CORM-2), a carbon
monoxide-liberating compound, on the expression of HO-1, NOS1, NOS2, CD11b/c, GFAP, and
mitogen-activated protein kinases (MAPK) in the LC. CoPP reduced inflammatory pain in different
time-dependent manners in WT and KO mice. Peripheral inflammation activated astroglia in the LC
of all genotypes and increased the levels of NOS1 and phosphorylated extracellular signal-regulated
kinase 1/2 (p-ERK 1/2) in WT mice. CoPP and CORM-2 enhanced HO-1 and inhibited astroglial
activation in all genotypes. Both treatments blocked NOS1 overexpression, and CoPP normalized ERK
1/2 activation. This study reveals an interaction between HO-1 and NOS1/NOS2 during peripheral
inflammation and shows that CoPP and CORM-2 improved HO-1 expression and modulated the
inflammatory and/or plasticity changes caused by peripheral inflammation in the LC.
Keywords: analgesia; carbon monoxide; heme oxygenase 1; inflammatory pain; locus coeruleus;
nitric oxide
1. Introduction
The effects of carbon monoxide and nitric oxide on the regulation of the nociceptive responses
induced by acute painful stimuli, chronic inflammation, or nerve injury and those associated with
diabetic neuropathy have been investigated [1–4], but the possible interaction among them has been
poorly evaluated.
Several studies demonstrated that, whereas carbon monoxide is a potent modulator of
inflammation and nociception, nitric oxide has a more complex role in the development and
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maintenance of chronic pain. That is, while treatment with carbon monoxide inhaled and/or released
by tricarbonyldichlororuthenium(II)dimer (CORM-2) exerted robust antiinflammatory [5,6] and
antinociceptive actions during inflammatory and neuropathic pain [2,7,8], both types of pain were
inhibited with the administration of selective nitric oxide synthase (NOS) inhibitors or in mice lacking
neuronal (NOS1-KO) or inducible (NOS2-KO) nitric oxide synthases [9–13].
More interesting is the detail that, although the interaction among carbon monoxide and nitric
oxide has been widely investigated at the vascular level [14–16], in the control of fewer, sepsis,
hemorrhagic shock, etc. [17,18], only few studies examined this interaction in pain regulation. In this
line, previous works revealed that carbon monoxide required the NOS pathway for its antinociceptive
effects, whereas nitric oxide effects were produced independently of the carbon monoxide system [19,20].
Nonetheless, the interaction among heme oxygenase 1 (HO-1) enzyme, principally responsible for the
antinociceptive effects induced by carbon monoxide [2], and NOS1 or NOS2 in inflammatory pain has
not been evaluated. In this study, we assessed this interaction by testing the antinociceptive effects
of cobalt protoporphyrin IX (CoPP), an HO-1 inducer, in both NOS1- and NOS2-deficient mice with
chronic peripheral inflammation.
Recent works revealed that the systemic administration of CoPP and CORM-2, besides inhibiting
neuropathic pain and blocking NOS1 and NOS2 over-expression in the spinal cords [2,21], activated
powerful anti-inflammatory and antioxidant responses in several brain areas [22]. Considering that
the locus coeruleus (LC) is implicated in the control of nociception [23] and both HO-1 [24,25] and
NOS1/NOS2 enzymes [26,27] are well expressed in it, our objective was to evaluate the potential
interaction between them in the LC of animals with inflammatory pain.
Several authors have demonstrated the relevant role played by glial cells in the development
and maintenance of pain [28]. Therefore, and considering the inhibitory effects induced by CoPP and
CORM-2 treatments on glial activation induced by sciatic nerve injury in the spinal cord and specific
brain areas such as amygdala and hippocampus [2,22], in this study, we also evaluated the effects of
these treatments on the expression of GFAP (an astroglial marker) and CD11b/c (a microglial marker)
in LC of animals with complete Freund’s adjuvant (CFA)-induced inflammatory pain.
It is well known that peripheral inflammation, in addition to induce the phosphorylation of
several mitogen-activated protein kinases (MAPK)—especially, the extracellular signal-regulated
kinase 1/2 (ERK 1/2) and c-Jun N-terminal kinase (JNK) in the spinal cord [29,30]—also activated ERK
1/2 in LC [31,32]. Considering that the systemic and peripheral administration of CoPP and other
antiinflammatory agents, such as diclofenac, normalized the up regulation of p-ERK 1/2 and p-JNK
induced by chronic pain in different brain areas [22,32], we examined the effects of CoPP and CORM-2
on the expression of p-ERK 1/2 and p-JNK in LC of animals with inflammatory pain.
Then, using wild-type (WT), NOS1-KO, and NOS2-KO mice with chronic peripheral inflammation,
we assessed the antinociceptive actions of the repeated administration of CoPP and the effects of CoPP
and CORM-2 treatments on the protein levels of HO-1, NOS1, NOS2, CD11b/c, GFAP, p-ERK 12 , and
p-JNK in the LC of these animals.
2. Results
2.1. Antinociceptive Effects of CoPP in WT, NOS1-KO, and NOS2-KO Mice
Mechanical allodynia and thermal hyperalgesia were assessed after 1, 4, 7, and 11 days of repeated
administration of CoPP or vehicle in WT, NOS1-KO, and NOS2-KO mice (Figure 1).
Our data showed that CFA injection caused mechanical allodynia in the ipsilateral paw of all
genotypes from day 3 to day 14 since CFA injection (p < 0.001; one-way ANOVA vs. their respective
contralateral paws). In NOS1-KO animals (Figure 1A), three-way ANOVA displayed significant effects
of the genotype on day 11 (p < 0.011), of the treatment on days 4, 7, and 11 (p < 0.020), and with respect
to the paw on days 0, 1, 4, 7, and 11 of CoPP treatment (p < 0.001). In addition, significant interactions
among genotype and treatment at days 7 and 11 (p < 0.042), genotype and paw at day 14 (p < 0.005),
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treatment and paw at days 4, 7, and 11 (p < 0.017), and genotype, treatment, and paw at days 7 and 11
of CoPP treatment (p < 0.019) were also demonstrated. Our results, besides confirming that NOS1-KO
mice had faster recovery of the mechanical allodynia than WT animals from days 10 to 14 after CFA
injection (p < 0.001, one-way ANOVA), demonstrated that mechanical allodynia caused by CFA was
further reduced in WT compared to NOS1-KO mice after 4 and 7 days of CoPP treatment (p < 0.001,
one-way ANOVA; Figure 1A).
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hyperalgesia (C,D) in ipsilateral (continuous lines) and contralateral paws (discontinuous lines) of 
WT, NOS1-KO, and NOS2-KO mice treated for 11 days with vehicle or CoPP at 4, 7, 10, and 14 days 
after complete Freund’s adjuvant (CFA) injection are shown. For each genotype, day and treatment 
were assessed; * denotes significant differences when compared with their respective contralateral 
paw, + denotes significant differences when compared with their respective ipsilateral paw treated 
with CoPP, and # denotes significant differences of the same treatment between genotypes (p < 0.05, 
one-way ANOVA, Student–Newman–Keuls test). Data are shown as mean values ± SEM; n = 8 
animals per group. 
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treatment and paw at days 4, 7, and 11 (p < 0.025), as well as among genotype, treatment, and paw at 
days 4, 7, and 11 days of CoPP treatment (p < 0.032) were evident. Therefore, although similar 
mechanical allodynia caused by CFA was observed in WT and NOS2-KO animals, the inhibitory 
effects of CoPP were stronger in WT that in NOS2-KO mice at 4 and 7 days of treatment (p < 0.001, 
Figure 1. Antiallodynic and antihyperalgesic effects of cobalt protoporphyrin IX (CoPP) in wild-type
(WT), neuronal nitric oxide synthase knock-out (NOS1-KO), and inducible nitric oxide synthase
knock-out (NOS2-KO) mice with peripheral inflammation. Mechanical allodynia (A,B) and thermal
hyperalgesia (C,D) in ipsilateral (continuous lines) and contralateral paws (discontinuous lines) of
WT, NOS1-KO, and NOS2-KO mice treated for 11 days with vehicle or CoPP at 4, 7, 10, and 14 days
after complete Freund’s adjuvant (CFA) injection are shown. For each genotype, day and treatment
were assessed; * denotes significant differences when compared with their respective contralateral
paw, + denotes significant differences when compared with their respective ipsilateral paw treated
with CoPP, and # denotes significant differences of the same treatment between genotypes (p < 0.05,
one-way ANOVA, Student–Newman–Keuls test). Data are shown as mean values ± SEM; n = 8 animals
per group.
In NOS2-KO animals (Figure 1B), three-way ANOVA also showed effects of treatment at days 1,
4, 7, and 11 (p < 0.007), and with respect to the paw at days 0, 1, 4, 7, and 11 of CoPP administration
(p < 0.001). Moreover, significant interactions amongst genotype and treatment at day 7 (p < 0.007),
treatment and paw at days 4, 7, and 11 (p < 0.025), as well as among genotype, treatment, and paw
at days 4, 7, and 11 days of CoPP treatment (p < 0.032) were evident. Therefore, although similar
mechanical allodynia caused by CFA was observed in WT and NOS2-KO animals, the inhibitory
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effects of CoPP were stronger in WT that in NOS2-KO mice at 4 and 7 days of treatment (p < 0.001,
one-way ANOVA, Figure 1B). In all genotypes, no treatment produced no effect on the respective
contralateral paw.
In all genotypes, peripheral inflammation also reduced the threshold for evoking ipsilateral paw
withdrawal to thermal stimulus from days 3 to 14 after CFA injection (p < 0.001; one-way ANOVA vs.
the corresponding contralateral paw) (Figure 1C,D).
In NOS1-KO animals, three-way ANOVA proved significant effects of treatment at days 1, 4, 7,
and 11 (p < 0.002) and of paw at days 0, 1, 4, 7, and 11 of CoPP administration (p < 0.001). Moreover,
significant interactions among genotype and treatment at day 4 (p < 0.008), treatment and paw at days
1, 4, 7, and 11 of CoPP treatment (p < 0.018), and among genotype, treatment, and paw at days 4 and 7
of CoPP treatment in NOS1-KO mice were demonstrated (p < 0.045) (Figure 1C). Therefore, although
similar thermal hyperalgesia induced by CFA was observed in both genotypes, its inhibition by CoPP
was higher in WT mice than in NOS1-KO animals at days 4 and 7 of treatment (p < 0.001, one-way
ANOVA).
In NOS2-KO mice, our data confirmed that the absence of this isoform improved the recovery
from thermal hyperalgesia induced by CFA (Figure 1D). In addition, significant effects of genotype at
days 7 and 11 (p < 0.010), treatment at days 1, 4, 7, and 11 (p < 0.004), and paw at days 0, 1, 4, 7, and 11
of CoPP treatment (p < 0.001) were demonstrated. Moreover, significant interactions among genotype
and treatment at days 4, 7, and 11 (p < 0.010), treatment and paw on days 1, 4, 7, and 11 (p < 0.005), as
well as among genotype, treatment, and paw at days 4, 7, and 11 of CoPP administration (p < 0.002)
were shown. Thus, the reduced thermal hyperalgesia induced by CoPP in WT mice was similar to that
induced by this compound in NOS2-KO animals during the overall experiment, except at day 7 of
treatment, in which it was higher in WT than in NOS2-KO mice (p < 0.05; one-way ANOVA). In all
genotypes, the absence of treatment did not produced any effect on the respective contralateral paw.
2.2. Effects of CoPP and CORM-2 on HO-1, NOS1, NOS2, CD11b/c, GFAP, p-ERK 1/2, and p-JNK Expression
in the LC of WT Mice with Peripheral Inflammation
Our data showed that CoPP and CORM-2 treatments augmented the expression of HO-1 in the
LC of CFA-injected WT mice (p < 0.001; one-way ANOVA vs. naïve and CFA-injected mice treated
with vehicle) (Figure 2A), and the enhanced expression of NOS1 (Figure 2B) and GFAP (Figure 2F)
caused by peripheral inflammation (p < 0.024; one-way ANOVA compared to the corresponding
naïve vehicle-treated animals) was normalized by both CoPP and CORM-2 treatments. Moreover, the
enhanced expression of p-ERK 1/2 caused by peripheral inflammation (p < 0.005; one-way ANOVA vs.
naïve vehicle-treated mice) was normalized by CoPP treatment (Figure 2G). None of these treatments
changed the unaltered expression of NOS2 (Figure 2C), CD11b/c (Figure 2D), or p-JNK (Figure 2H) in
the LC of CFA-injected mice.
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Figure 2. Effects of CoPP and tricarbonyldichlororuthenium(II) dimer (CORM-2) on the protein levels
of HO-1, NOS1, NOS2, CD11b/c, GFAP, p-ERK 1/2, and p-JNK in the LC of WT mice. Protein levels
of HO-1 (A), NOS1 (B), NOS2 (C), CD11b/c (D), GFAP (F), p-ERK 1/2 (G), and p-JNK (H) in the LC
from CFA-injected WT mice treated with vehicle, CORM-2, or CoPP are represented. These levels in
naïve mice treated with vehicle are also represented as controls. In all panels, * denotes significant
differences vs. naïve vehicle-treated mice, + denotes significant differences vs. CFA-injected mice
treated with vehicle, # denotes significant differences vs. CFA-injected mice treated with CORM-2, and
$ denotes significant differences vs. CFA-injected mice treated with CoPP (p < 0.05, one-way ANOVA,
Student–Newman–Keuls test). Examples of western blots for HO-1 (32 kDa), NOS1 (160 kDa), NOS2
(100 kDa), CD11b/c (160 kDa), GFAP (50 kDa), GAPDH (37 kDa), p-ERK 1/2/total ERK 1/2 (42–44 kDa),
and p-JNK/total JNK (46–54 kDA) are shown (E). The levels of phosphorylated proteins are indicated
relative to the corresponding total protein levels, while the levels of the remaining proteins are relative
to those of GAPDH. Results re xpressed as mean ± SEM; n = 4 sampl s per group.
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2.3. Effects of CoPP and CORM-2 on HO-1, NOS2, CD11b/c, GFAP, p-ERK 1/2, and p-JNK Expression in the
LC of NOS1-KO Mice with Peripheral Inflammation
Similar to what observed in WT mice, while peripheral inflammation did not modify the protein
levels of HO-1 in the LC of NOS1-KO animals (Figure 3A), HO-1 expression was significantly augmented
in CoPP- and CORM-2-treated animals (p < 0.001; one-way ANOVA vs. naïve and CFA-injected mice
treated with vehicle). None of these treatments altered the expression of NOS2 (Figure 3B), CD11b/c
(Figure 3C), and p-JNK (Figure 3G) in the LC of CFA-injected NOS1-KO mice and, although peripheral
inflammation did not activate ERK 1/2, an increased expression of p-ERK 1/2 was detected in NOS1-KO
mice treated with CORM-2 (p < 0.019 vs. naïve and CFA-injected mice treated with vehicle or CoPP)
(Figure 3F). In addition, the overexpression of GFAP induced by CFA was completely inhibited by
CORM-2 and CoPP treatments (Figure 3E).
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Figure 3. Effects of CoPP and CORM-2 on the protein levels of HO-1, NOS2, CD11b/c, GFAP, p-ERK 1/2,
and p-JNK in the LC of NOS1-KO mice. Protein levels of HO-1 (A), NOS2 (B), CD11b/c (C), GFAP (E),
p-ERK 1/2 (F), and p-JNK (G) in the LC of CFA-injected NOS1-KO mice treated with vehicle, CORM-2,
or CoPP are represented. These levels from naï e mice treated with vehicle are also represented as
controls. In all panels, * represents significant differe ces vs. naïve vehicle-treated mice, + represents
significant differences vs. CFA-injected mice tr ated with vehicle, # r presents significant differences
vs. CFA-injected mice treated with CORM-2, and $ represents significant differences vs. CFA-injected
mice treated with CoPP (p < 0.05, one-way ANOVA, Student–Newman–Keuls test). Examples of
western blots for HO-1(32 kDa), NOS2 (100 kDa), CD11b/c (160 kDa), GFAP (50 kDa), GAPDH (37 kDa),
p-ERK 1/2/total ERK 1/2 (42–44 kDa), and p-JNK/total JNK (46–54 kDA) are shown (D). The levels of
phosphorylated proteins are relative to the total levels of the corresponding proteins, while the levels
of the remaining proteins are relative to those of GAPDH. Results are expressed as mean ± SEM; n = 4
samples per group.
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2.4. Effects of CoPP and CORM-2 on HO-1, NOS1, CD11b/c, GFAP, p-ERK 1/2, and p-JNK Expression in the
LC from NOS2-KO Mice with Peripheral Inflammation
Similar to what observed in NOS1-KO mice, although peripheral inflammation did not change
the expression of HO-1 in the LC of NOS2-KO mice (Figure 4A), CoPP and CORM-2 treatments
significantly enhanced its expression (p < 0.007; one-way ANOVA vs. naïve and CFA-injected mice
treated with vehicle). Moreover, repeated treatment with CORM-2 or CoPP significantly reduced the
enhanced expression of GFAP induced by peripheral inflammation in the LC (Figure 4E). In contrast,
neither CORM-2 nor CoPP treatments altered the unchanged levels of NOS1 (Figure 4B), CD11b/c
(Figure 4C), p-ERK 1/2 (Figure 4F), or p-JNK (Figure 4G) in the LC of CFA-injected NOS2-KO mice.
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Figure 4. Effects of CoPP and CORM-2 on the protein levels of HO-1, NOS1, CD11b/c, GFAP, p-ERK 1/2,
and p-JNK in the LC of NOS2-KO mice. Protein levels of HO-1 (A), NOS1 (B), CD11b/c (C), GFAP (E),
p-ERK 1/2 (F), and p-JNK (G) in the LC of CFA-injected NOS2-KO mice treated with vehicle, CORM-2,
or CoPP are represented. These levels from naïve mice treated with vehicle are also represented as
controls. In all panels, * denotes significant differences vs. naïve vehicle-treated mice, + represents
significant differences vs. CFA-injected mice treated with vehicle, # represents significant differences vs.
CFA-injected mice treated with CORM-2, and $ represents significant differences vs. CFA-injected mice
treated with CoPP (p < 0.05, one-way ANOVA, Student–Newman–Keuls test). Examples of western
blots for HO-1 (32 kDa), NOS1 (160 kDa), CD11b/c (160 kDa), GFAP (50 kDa), GAPDH (37 kDa),
p-ERK 1/2/total ERK 1/2 (42–44 kDa), and p-JNK/total JNK (46–54 kDA) are shown (D). The levels of
phosphorylated proteins are relative to the total levels of the corresponding proteins, while the levels
of the remaining proteins are relative to those of GAPDH. Each column represents the mean, and the
vertical bars indicate the SEM; n = 4 samples per group.
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3. Discussion
This study revealed that the systemic repeated administration of CoPP differentially inhibited
allodynia and hyperalgesia caused by CFA in WT and NOS1-KO or NOS2-KO mice. Moreover,
CoPP and CORM-2 treatments induced HO-1 overexpression and inhibited activated astroglia in
the LC of all genotypes. Both treatments also normalized the upregulation of NOS1 caused by
peripheral inflammation in WT mice. Moreover, peripheral inflammation activated ERK 1/2 in the
LC of WT animals but not in NOS1-KO or NOS2-KO mice, and only CoPP treatment inhibited ERK
1/2 phosphorylation.
Our findings indicated that treatment with CoPP throughout 11 consecutive days inhibited
the mechanical and thermal hypersensitivity triggered by peripheral inflammation in a different
time-dependent manner in WT and NOS1- or NOS2-deficient mice. That is, the antiallodynic and
antihyperalgesic effects of CoPP in WT mice were stronger than in NOS1-KO or NOS2-KO mice after 4
to 7 days of treatment. These data demonstrate the involvement of both NOS isoforms in the analgesic
effects of CoPP during inflammatory pain and reveal an interaction between HO-1 and NOS1/NOS2
isoenzymes in chronic inflammatory pain conditions. Our results are in agreement with the analgesic
effects induced by HO-1 inducers during acute [33] and neuropathic pain [2,4,21,34,35]. Our findings
also support the improved antinociceptive actions of carbon monoxide, liberated by CORM-2, in WT
versus both KO mice with inflammatory pain [20] and further demonstrate the crucial role played
by HO-1 in the interaction between carbon monoxide and nitric oxide during the management of
inflammatory pain.
It is well known that LC is a supraspinal structure implicated in the control of pain, but the effects
induced by chronic treatment with CoPP or CORM-2 during inflammatory pain in this brain area had
not been investigated previously. In previous works, we showed that the repetitive administration
of CoPP or CORM-2 upregulated HO-1 levels in paws and dorsal root ganglia of animals with
inflammatory pain [20,36] as well as in spinal cords and sciatic nerves from diabetic mice [4,35].
Recently, an augmented expression of HO-1 was also demonstrated in the prefrontal cortex and
hippocampus of WT mice with neuropathic pain repeatedly treated with CORM-2 or CoPP [22]. In this
study, we demonstrated for the first time that, under inflammatory pain circumstances, both HO-1 and
carbon monoxide inducers improved HO-1 levels in the LC of WT, NOS1-KO, and NOS2-KO mice.
These data agree with those reporting augmented expression of HO-1 induced by CoPP and CORM-2
treatments in the central nervous system of WT mice with neuropathic pain [22] and further support
data showing the upregulation of this enzyme in the paw of CFA-injected NOS1- and NOS2-deficient
mice systemically treated with CORM-2 [20]. Our results reveal the central antioxidant effects induced
by these treatments during inflammatory pain in the presence or absence of NOS enzymes and suggest
that the enhanced expression of HO-1 produced by CoPP and CORM-2 in the LC might be involved in
the antinociceptive effects of these compounds during inflammatory pain.
In this study, an increased expression of NOS1, but not of NOS2, was also revealed in the LC of
WT mice with peripheral inflammation. This is in agreement with observations in inflamed paws,
showing the relevant role performed by NOS1 in the maintenance of inflammatory pain in the central
and peripheral nervous system [37,38]. Moreover, the fact that the systemic administration of CoPP
and CORM-2 inhibited NOS1-upregulation in the LC revealed the central anti-inflammatory effects
induced by these compounds during inflammatory pain. In contrast to NOS1, no changes in the
protein levels of NOS2 were observed in the LC of these animals. These data are in agreement with the
observed lack of changes in the expression of this enzyme in the dorsal root ganglia and spinal cords
of WT mice at day 14 after CFA injection [30]. All of these data suggest that, in chronic peripheral
inflammatory pain conditions, the effects induced by CoPP and CORM-2 treatments in the LC are
mainly produced via regulating NOS1 expression.
The implication of spinal glia in the progress of chronic pain is well recognized, but less is known
about its activation in supraspinal structures after peripheral inflammatory pain. Thus, in this study,
we examined if peripheral inflammation induced astroglial and/or microglial activation in the LC
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14 days after CFA injection. Our results showed that CFA induced astroglial activation in the LC of
WT, NOS1-KO, and NOS2-KO mice. No changes in the expression of CD11b/c (a microglial marker)
were detected in the LC of any genotype, confirming the crucial role of astroglia in the maintenance of
chronic inflammatory pain [39,40]. Interestingly, CORM-2 and CoPP inhibited the overexpression of
GFAP (an astroglial marker) in the LC of all genotypes, showing that the systemic administration of
these compounds has anti-inflammatory properties in the LC. Our results also suggest the participation
of astroglia in the analgesic effects of CORM-2 and CoPP during inflammatory pain. These findings
are supported by the antinociceptive actions produced by the treatment with selective astroglial cell
inhibitors, such as fluorocitrate and α-aminoadipate, during chronic pain [41,42].
The participation of MAPK in the development and maintenance of chronic pain is well
documented [29,43]. Thus, under inflammatory pain conditions, the expression of ERK1/2 and
JNK are activated in the spinal cord [30]. In this work, we analyzed the actions of CoPP and CORM-2
on the expression of these MAPK in the LC of WT and NOS-deficient mice. As occurs in other
animal pain models [32,44], CFA-induced peripheral inflammation activated ERK 1/2 in the LC of WT
mice. Curiously, this effect was not detected in NOS1-KO or NOS2-KO mice, suggesting that nitric
oxide generated by these isoforms is involved in the plasticity changes induced by chronic peripheral
inflammation in LC. Moreover, while CoPP normalized ERK 1/2 activation in WT animals, CORM-2
did not alter or enhanced p-ERK 1/2 levels in WT and NOS1-KO mice, respectively, thus revealing
that ERK 1/2 activation induced by peripheral inflammation in the LC might be modulated by the
systemic treatment with the antioxidant enzyme HO-1. The lack of effects of CORM-2 on the expression
of p-ERK 1/2 in WT mice confirmed similar results obtained in the central and peripheral nervous
system of animals with neuropathic pain [22,45], suggesting that CORM-2 might act via inhibiting
other pathways implicated in the regulation of inflammatory pain. Finally, although more studies are
required to explain this phenomenon, the increased expression of p-ERK 1/2 induced by CORM-2 in
NOS1-KO mice is an indication of the plausible involvement of NOS1 in ERK 1/2 activation induced by
CORM-2 in WT mice.
In conclusion, this study reveals an interaction between HO-1 and NOS1/NOS2 enzymes during
peripheral inflammation and shows that CoPP treatment inhibited inflammatory pain by improving
HO-1 expression and decreasing NOS1 overexpression, which would restrict the activation of astroglia
and subsequent ERK 1/2 activation in the LC.
4. Materials and Methods
4.1. Animals
Experiments were performed in male NOS1-KO (C57BL/6 J background) and NOS2-KO mice
(C57BL/6 J background) acquired from Jackson Laboratories (Bar Harbor, ME, USA). WT mice
with the same genetic background (C57BL/6J) were obtained from Envigo Laboratories (Barcelona,
Spain). Animals weighing 21–25 g were housed under 12 h/12 h light/dark conditions and controlled
temperature (22◦C) and humidity (66%). Animals with free access to food and water were utilized
after 7 days acclimatization to the housing conditions. Experiments were performed between 9:00 a.m.
and 5:00 p.m., executed in accordance to the animals guidelines of the European Communities Council
(86/609/ECC, 90/679/ECC; 98/81/CEE, 2003/65/EC, and Commission Recommendation 2007/526/EC),
and approved by the Comitè d’Ètica en Experimentació Animal of Universitat Autònoma de Barcelona
(number: 1325R5, 29 November 2013). Maximal efforts to minimize the quantity of mice employed
and their suffering were made.
4.2. Chronic Inflammatory Pain Induction
Chronic inflammatory pain was provoked with the sub-plantar injection of CFA (30 µL)
(Sigma-Aldrich, St. Louis, MO, USA) into the right hind paw under brief anesthetic conditions
with isoflurane (3% induction, 2% maintenance) according to the method used by our group [38].
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Mechanical allodynia and thermal hyperalgesia were assessed with the von Frey filaments and plantar
tests, respectively.
4.3. Nociceptive Behavioral Tests
Mechanical allodynia was estimated by determining the hind paw withdrawal response to von
Frey filament stimulation. Thus, mice were positioned in methacrylate cylinders (20 cm high, 9 cm
diameter) with a wire grid bottom through which the von Frey filaments (North Coast Medical, Inc.,
San Jose, CA, USA) were applied according to the up–down paradigm [46]. A filament of 0.4 g
was applied first, and one of 3.5 g as a cut-off. The strength of the next filament was reduced or
augmented depending on the response. Withdrawal, shaking, or licking the paw were considered
nociceptive-like reactions.
Thermal hyperalgesia was assessed according to previous methods [47]. Paw withdrawal latency
in reply to a radiant heat was assessed using the plantar test device (Ugo Basile, Italy). Mice were
placed in methacrylate cylinders, 20 cm high × 9 cm diameter, situated on a glass surface. The heat
source was situated under the plantar surface of the hind paw and activated with a light beam. A cut-off
time of 12 s was utilized to avoid tissue damage. The mean paw withdrawal latencies were calculated
from the average of 2–3 separate trials, taken at 5 min intervals to prevent thermal sensitization.
In both tests, the animals were habituated to the environment for 1 h before the experiment. Both
ipsilateral and contralateral paws were tested.
4.4. Western Blot Analysis
Mice were euthanized by cervical dislocation after 0 (naïve) or 14 days from CFA injection. LC
were extracted and preserved at 80 ◦C until use. Samples from four animals were combined to have
satisfactory proteins levels to analyze HO-1, NOS1, NOS2, CD11b/c, GFAP, pERK1/2/ERK1/2, and
p-JNK/JNK in LC by western blot assay. The homogenization of tissues was made in cold lysis
buffer (50 mM Tris·Base, 150 nM NaCl, 1% NP-40, 2 mM EDTA, 1mM phenylmethylsulfonyl fluoride,
0.5 Triton X-100, 0.1% sodium dodecyl sulfate, 1 mM Na3VO4, 25 mM NaF, 0.5% protease inhibitor
cocktail, and 1% phosphatase inhibitor cocktail). All reagents were acquired from Sigma-Aldrich
(St. Louis, MO, USA), except for NP-40 which was bought from Calbiochem (Darmstadt, Germany).
After solubilization for 1 h at 4 ◦C, crude homogenates were sonicated for 10 s and centrifuged at
700× g for 15 min at 4 ◦C. The supernatant (60 µg of total protein) was mixed with 4X Laemmli
loading buffer and loaded onto a 4% stacking/10% separating sodium dodecyl sulfate polyacrylamide
gels. Proteins were electrophoretically transferred onto a polyvinylidene fluoride membrane for
120 min and successfully blocked with phosphate-buffered saline containing 5% nonfat dry milk
or Tris-buffered saline with Tween 20 containing 5% bovine serum albumin for 75 min; they were
then incubated with specific rabbit primary antibodies anti HO-1 (1:300; Abcam, Cambridge, United
Kingdom), NOS1 (1:200; Abcam, Cambridge, United Kingdom), NOS2 (1:100; Abcam, Cambridge,
United Kingdom), CD11b/c (1:160, Novus Biologic, Littleton, CO, USA), GFAP (1:3000, Novus Biologic,
Littleton, CO, USA), phospho-ERK 1/2 and total ERK 1/2 (1:250; Cell Signaling Technology, Danvers,
MA, USA), phospho-JNK and total JNK (1:250; Cell Signaling Technology, Danvers, MA, USA), or
glyceraldehyde-3-phosphate dehydrogenase antibody (GAPDH) (1:5000, Merck, Billerica, MA, USA)
overnight at 4 ◦C. The blots were then incubated with anti-rabbit secondary polyclonal antibodies
conjugated to horseradish peroxidase (GE Healthcare, Little Chalfont, Buckinghamshire, UK) for 1 h
at r.t. Proteins were detected by using chemiluminescence reagents provided in the ECL kit (GE,
Healthcare, Little Chalfont, Buckinghamshire, UK) and exposure onto hyperfilms (GE, Healthcare,
Little Chalfont, Buckinghamshire, UK). Blots’ intensity was quantified by densitometry.
4.5. Experimental Procedure
In WT, NOS1-KO, and NOS2-KO mice baseline responses were established in von Frey filaments
and plantar tests. All mice were tested at days 3, 4, 7, 10, and 14 after CFA injection.
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The animals were intraperitoneally injected with vehicle, 2.5 mg/kg CoPP, or 5 mg/kg CORM-2,
two times a day for 11 days, from day 4 to day 14 after CFA injection, according to earlier studies [2,20].
The antinociceptive effects of CoPP were evaluated at 1, 4, 7, and 11 days from its administration. The
investigator who made these experiments was blinded to the treatments.
We assessed the effects of CoPP and CORM-2 on the expression of HO-1, NOS1, NOS2, CD11b/c,
GFAP, pERK 1/2, ERK 1/2, p-JNK, and JNK in the LC of WT, NOS1-KO, or NOS2-KO mice 14 days after
CFA injection by western blot assay. For each genotype, naïve mice treated with vehicle were used as
controls (n = 4 samples per group).
4.6. Drugs
CoPP was purchased from Frontier scientific (Livchem GmbH & Co., Frankfurt, Germany), and
CORM-2 from Sigma-Aldrich (St. Louis, MO, USA). Both compounds were dissolved in dimethyl
sulfoxide (DMSO; 1% solution in saline), freshly prepared before use, and injected intraperitoneally at
10 mL/kg of body weight, 3 h before testing, twice a day. Control animals received the same volume
of vehicle.
4.7. Statistical Analysis
The SPSS (version 17 for Windows, IBM, Madrid, Spain) was used to perform the statistical analysis.
Data were expressed as mean ± standard error of the mean (SEM). For each behavioral test and time
evaluated, the antiallodynic and antihyperalgesic effects of CoPP were evaluated by using a three-way
analysis of variance (ANOVA) (genotype, treatment, and paw as factors of variation) followed by the
pertinent one-way ANOVA and Student–Newman–Keuls test whenever required. For each genotype,
alterations in the protein levels of HO-1, NOS1, NOS2, CD11b/c, GFAP, p-ERK 1/2, ERK 1/2, p-JNK, and
JNK in the LC of CFA-injected mice treated with CORM-2, CoPP, or vehicle vs. naïve vehicle-treated
mice were analyzed by a one-way ANOVA followed by the Student–Newman–Keuls test. A p < 0.05
was considered significant.
Author Contributions: Formal analysis, P.M., R.A.C., and J.M.-G.; Funding acquisition, C.R.A.L.-P. and O.P.;
Investigation, P.M., R.A.C., J.M.-G., A.F.D., S.P., and S.L.; Supervision, C.R.A.L.-P. and O.P.; Writing, O.P. All authors
read and approved the final manuscript.
Funding: This work was supported by Ministerio de Economía y Competitividad, Instituto de Salud Carlos III,
Madrid, Spain and Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea [Grants: PS0900968 and
PI1400927], and CAPES/PROEX, CNPq, Brasil [401472/2014-0].
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
HO-1 Heme oxygenase 1
LC Locus coeruleus
WT Wild-type
NOS1 Neuronal nitric oxide synthase
NOS2 Inducible nitric oxide synthase
KO Knockout
CFA Complete Freund’s adjuvant
CoPP Cobalt protoporphyrin IX
CORM-2 Tricarbonyldichlororuthenium(II) dimer
ERK 1/2 Extracellular signal-regulated kinase 1/2
JNK c-Jun N-terminal kinase
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GFAP Glial fibrillary acidic protein
SEM Standard error of the mean
ANOVA Analysis of variance
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